1-2 of 2
David Hynds
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

Free
Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Yeow-Tee Goh, MBBS, MMed, Oliver G. Ottmann, MD, Hironobu Minami, MD PhD, Delphine Rea, MD PhD, Fabian Lang, MD, Michael J. Mauro, MD, Daniel J. DeAngelo, MD PhD, Moshe Talpaz, MD, Andreas Hochhaus, Prof. Dr., Massimo Breccia, MD, Jorge E. Cortes, MD, Michael C. Heinrich, MD, Jeroen Janssen, MD, Juan-Luis Steegmann, MD PhD, François-Xavier Mahon, MD PhD, Raina Duan, PhD, Varsha Iyer, David Hynds, MS, Gary J. Vanasse, MD, Dong-Wook Kim, MD PhD
Journal: Blood
Blood (2016) 128 (22): 625.
https://doi.org/10.1182/blood.V128.22.625.625
Published: 2016
Journal Articles

Phase 1 Study Of The Novel Pan-Pim Kinase Inhibitor LGH447 In Patients With Relapsed/ Refractory Multiple Myeloma

Free
Marc S Raab, MD, Enrique M. Ocio, Sheeba K. Thomas, M.D., Andreas Günther, Daniel Lebovic, MD, Shaji K Kumar, MD, Andrzej J. Jakubowiak, MD, PhD, Dongweon Song, Fang Xiang, David Hynds, K. Gary Vanasse, M.D., Yeow Tee Goh, MD
Journal: Blood
Blood (2013) 122 (21): 3186.
https://doi.org/10.1182/blood.V122.21.3186.3186
Published: 2013